WO2006067198A3 - Nouvelles entites biologiques et utilisation ciblee de celles-ci - Google Patents

Nouvelles entites biologiques et utilisation ciblee de celles-ci Download PDF

Info

Publication number
WO2006067198A3
WO2006067198A3 PCT/EP2005/057061 EP2005057061W WO2006067198A3 WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3 EP 2005057061 W EP2005057061 W EP 2005057061W WO 2006067198 A3 WO2006067198 A3 WO 2006067198A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted use
engineered enzymes
disease
defined specificity
engineered
Prior art date
Application number
PCT/EP2005/057061
Other languages
English (en)
Other versions
WO2006067198A2 (fr
Inventor
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Original Assignee
Direvo Biotech Ag
Voetsmeier Christian
Ulrich Haupts
Andre Koltermann
Andreas Scheidig
Ulrich Kettling
Wayne Michael Coco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direvo Biotech Ag, Voetsmeier Christian, Ulrich Haupts, Andre Koltermann, Andreas Scheidig, Ulrich Kettling, Wayne Michael Coco filed Critical Direvo Biotech Ag
Priority to EP05823713A priority Critical patent/EP1827486A2/fr
Publication of WO2006067198A2 publication Critical patent/WO2006067198A2/fr
Publication of WO2006067198A3 publication Critical patent/WO2006067198A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode pour traiter une maladie. Cette méthode consiste à appliquer un médicament comprenant une protéase qui présente une spécificité définie, capable d'hydrolyser des liaisons peptidiques spécifiques à l'intérieur d'un substrat cible lié à ladite maladie. Les protéases présentant une telle spécificité définie peuvent également être utilisées à des fins thérapeutiques ou diagnostiques liées.
PCT/EP2005/057061 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci WO2006067198A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05823713A EP1827486A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106903.0 2004-12-22
EP04106903 2004-12-22

Publications (2)

Publication Number Publication Date
WO2006067198A2 WO2006067198A2 (fr) 2006-06-29
WO2006067198A3 true WO2006067198A3 (fr) 2007-01-04

Family

ID=36602119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/057061 WO2006067198A2 (fr) 2004-12-22 2005-12-21 Nouvelles entites biologiques et utilisation ciblee de celles-ci

Country Status (2)

Country Link
EP (1) EP1827486A2 (fr)
WO (1) WO2006067198A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
AU2005244271B2 (en) 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
KR20170014023A (ko) 2006-07-05 2017-02-07 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
WO2010129287A2 (fr) 2009-04-27 2010-11-11 The Board Of Trustees Of The University Of Illinois Enzymes de dégradation d'hémicellulose
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
CN105829350B (zh) * 2013-12-17 2021-01-08 诺和诺德股份有限公司 肠激酶可切割的多肽
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2970246T3 (es) 2015-03-27 2024-05-27 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
EP3833381B1 (fr) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (fr) * 2002-05-10 2003-11-20 Direvo Biotech Ag Procede de production de proteases a sequences specifiques par evolution dirigee et utilisation de celles-ci
WO2004067737A2 (fr) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (fr) * 2003-06-18 2004-12-29 Direvo Biotech Ag Nouvelles entites biologiques et leur utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
WO2003095670A2 (fr) * 2002-05-10 2003-11-20 Direvo Biotech Ag Procede de production de proteases a sequences specifiques par evolution dirigee et utilisation de celles-ci
WO2004067737A2 (fr) * 2003-01-30 2004-08-12 Novozymes A/S Subtilases
WO2004113521A1 (fr) * 2003-06-18 2004-12-29 Direvo Biotech Ag Nouvelles entites biologiques et leur utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTAMIRANO M M ET AL: "Directed evolution of new catalytic activity using the alpha/beta-barrel scaffold", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 403, no. 6770, 10 February 2000 (2000-02-10), pages 617 - 622, XP002173865, ISSN: 0028-0836 *
COOMBS G.S.: "Directing sequence-specific proteolysis to new targets.", J BIOL. CHEM., vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4323 - 4328, XP002401171 *
HEDSTROM E ET AL: "CONVERTING TRYPSIN TO CHYMOTRYPSIN: THE ROLE OF SURFACE LOOPS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 255, no. 5049, 6 March 1992 (1992-03-06), pages 1249 - 1253, XP001179164, ISSN: 0036-8075 *
KURTH T ET AL: "Engineering the S1' subsite of trypsin: design of a protease which cleaves between dibasic residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, 18 August 1998 (1998-08-18), pages 11434 - 11440, XP002218040, ISSN: 0006-2960 *
SICES H J AND KRISTIE T M: "A genetic screen for the isolation of site-specific proteases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, March 1998 (1998-03-01), pages 2828 - 2833, XP002306297, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006067198A2 (fr) 2006-06-29
EP1827486A2 (fr) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2006067198A3 (fr) Nouvelles entites biologiques et utilisation ciblee de celles-ci
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
WO2007081516A3 (fr) Promedicaments specifiques a des tissus
MXPA05003493A (es) Metodos para generar y seleccionar proteasas con especificidad alterada.
WO2005118634A3 (fr) Composes peptidomimetiques helicoidaux a activite amelioree
EP2175834B8 (fr) Formulation de protéine de fusion glp-1-fc
WO2006052718A3 (fr) Utilisation therapeutique d'inhibiteurs de farnesyltransferase et procedes de controle de leur efficacite
WO2007016476A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
WO2005097103A3 (fr) Traitement du diabete et du syndrome metabolique au moyen d'inhibiteurs de la cathepsine b
WO2007117482A3 (fr) Inhibiteurs de la rénine
WO2004065423A3 (fr) Molecules de reconnaissance pour le traitement et la detection de tumeurs
WO2005120476A3 (fr) Nouvelle utilisation de composes peptidiques pour le traitement de la sclerose laterale amyotrophique
WO2010074588A8 (fr) Composés pharmaceutiques
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2006023866A3 (fr) Acides thiazolo-naphthyliques
MX2007008065A (es) Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
WO2007117557A3 (fr) Diaminopropanols inhibiteurs de rénine
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
WO2007109155A3 (fr) dosages pour la detection d'anticorps anti enzymes lysosomales
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
WO2005074904A3 (fr) Composes de silane en tant qu'inhibiteurs de cysteine protease
WO2005112987A3 (fr) Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
WO2007121124A3 (fr) Composés organiques et leurs utilisations
WO2004110376A3 (fr) Antagonistes de ccr-2 permettant de traiter une douleur neuropathique
WO2006114105A8 (fr) Methodes permettant de traiter les saignements

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005823713

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005823713

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005823713

Country of ref document: EP